14,918 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Purchased by Boothbay Fund Management LLC

Boothbay Fund Management LLC acquired a new stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Rating) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,918 shares of the company’s stock, valued at approximately $147,000.

Several other institutional investors have also added to or reduced their stakes in EWTX. JPMorgan Chase & Co. lifted its holdings in Edgewise Therapeutics by 23.4% during the first quarter. JPMorgan Chase & Co. now owns 27,166 shares of the company’s stock valued at $263,000 after purchasing an additional 5,156 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in Edgewise Therapeutics by 55.4% during the first quarter. MetLife Investment Management LLC now owns 23,355 shares of the company’s stock valued at $227,000 after purchasing an additional 8,328 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Edgewise Therapeutics by 20.8% in the first quarter. Rhumbline Advisers now owns 36,861 shares of the company’s stock worth $358,000 after buying an additional 6,350 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Edgewise Therapeutics by 0.4% in the first quarter. BlackRock Inc. now owns 2,055,160 shares of the company’s stock worth $19,934,000 after buying an additional 7,557 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Edgewise Therapeutics by 1.0% in the first quarter. Vanguard Group Inc. now owns 1,211,093 shares of the company’s stock worth $11,748,000 after buying an additional 11,693 shares in the last quarter.

Edgewise Therapeutics Trading Down 6.7 %

Shares of Edgewise Therapeutics stock opened at $8.80 on Tuesday. Edgewise Therapeutics, Inc. has a 12-month low of $5.41 and a 12-month high of $14.33. The company has a market cap of $556.69 million, a price-to-earnings ratio of -6.93 and a beta of -0.07. The company’s 50-day moving average price is $9.99 and its 200-day moving average price is $9.82.

Edgewise Therapeutics Company Profile

(Get Rating)

Edgewise Therapeutics, Inc, a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.